Edgestream Partners, L.P. Biomarin Pharmaceutical Inc Transaction History
Edgestream Partners, L.P.
- $3.48 Billion
- Q2 2025
A detailed history of Edgestream Partners, L.P. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Edgestream Partners, L.P. holds 129,560 shares of BMRN stock, worth $7.2 Million. This represents 0.2% of its overall portfolio holdings.
Number of Shares
129,560
Previous 60,632
113.68%
Holding current value
$7.2 Million
Previous $4.29 Million
66.15%
% of portfolio
0.2%
Previous 0.15%
Shares
10 transactions
Others Institutions Holding BMRN
# of Institutions
675Shares Held
185MCall Options Held
1.31MPut Options Held
1.1M-
Black Rock Inc. New York, NY22.7MShares$1.26 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$1.06 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA15.8MShares$876 Million0.71% of portfolio
-
Dodge & Cox San Francisco, CA15.1MShares$840 Million0.5% of portfolio
-
Viking Global Investors LP12.3MShares$683 Million2.14% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $10.3B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...